These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25078395)

  • 21. Interferon-based treatment of chronic hepatitis C.
    Souvignet C; Lejeune O; Trepo C
    Biochimie; 2007; 89(6-7):894-8. PubMed ID: 17570576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fatty Acids Induce a Pro-Inflammatory Gene Expression Profile in Huh-7 Cells That Attenuates the Anti-HCV Action of Interferon.
    Tse E; Helbig KJ; Van der Hoek K; McCartney EM; Van der Hoek M; George J; Beard MR
    J Interferon Cytokine Res; 2015 May; 35(5):392-400. PubMed ID: 25588104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring of liver metabolic function during interferon-alpha therapy and its relationship to treatment outcome in chronic hepatitis C patients.
    Giannini E; Fasoli A; Romagnoli P; Botta F; Fumagalli A; Polegato S; Sola S; Ceppa P; Testa R
    Hepatogastroenterology; 2002; 49(45):778-82. PubMed ID: 12063989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Iron as comorbid factor in chronic hepatitis C].
    Erhardt A; Hauck K; Häussinger D
    Med Klin (Munich); 2003 Dec; 98(12):685-91. PubMed ID: 14685669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes.
    Fortunato G; Calcagno G; Bresciamorra V; Salvatore E; Filla A; Capone S; Liguori R; Borelli S; Gentile I; Borrelli F; Borgia G; Sacchetti L
    J Interferon Cytokine Res; 2008 Mar; 28(3):141-52. PubMed ID: 18338947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C.
    Huang Y; Feld JJ; Sapp RK; Nanda S; Lin JH; Blatt LM; Fried MW; Murthy K; Liang TJ
    Gastroenterology; 2007 Feb; 132(2):733-44. PubMed ID: 17258724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.
    Kohjima M; Yoshimoto T; Enjoji M; Fukushima N; Fukuizumi K; Nakamura T; Kurokawa M; Fujimori N; Sasaki Y; Shimonaka Y; Murata Y; Koyama S; Kawabe K; Haraguchi K; Sumida Y; Harada N; Kato M; Kotoh K; Nakamuta M
    World J Gastroenterol; 2015 Mar; 21(11):3291-9. PubMed ID: 25805936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of soluble interferon Alfa/Beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C.
    Mizukoshi E; Kaneko S; Kaji K; Terasaki S; Matsushita E; Muraguchi M; Ohmoto Y; Kobayashi K
    Hepatology; 1999 Nov; 30(5):1325-31. PubMed ID: 10534358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of transferrin receptor 2 in hepatic accumulation of iron in patients with chronic hepatitis C.
    Mifuji R; Kobayashi Y; Ma N; Qiang QL; Urawa N; Horiike S; Iwasa M; Kaito M; Malavasi F; Adachi Y
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):144-51. PubMed ID: 16706826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Breakthrough" during interferon therapy for chronic hepatitis C. Overview on the diagnosis, possible aetiology and recommendations for management.
    Colloredo G; Roffi L; Bellati G
    Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):333-7. PubMed ID: 9759607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies.
    Larrea E; Aldabe R; Molano E; Fernandez-Rodriguez CM; Ametzazurra A; Civeira MP; Prieto J
    Gut; 2006 Aug; 55(8):1188-96. PubMed ID: 16120756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon research: a brief history.
    Kunzi MS; Pitha PM
    Methods Mol Med; 2005; 116():25-35. PubMed ID: 16000852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist.
    Best SM; Morris KL; Shannon JG; Robertson SJ; Mitzel DN; Park GS; Boer E; Wolfinbarger JB; Bloom ME
    J Virol; 2005 Oct; 79(20):12828-39. PubMed ID: 16188985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Cell Profiling of IFN-λ Response Shows pDCs Express Highest Level of IFN-λR1 and Are Directly Responsive via the JAK-STAT Pathway.
    Kelly A; Robinson MW; Roche G; Biron CA; O'Farrelly C; Ryan EJ
    J Interferon Cytokine Res; 2016 Dec; 36(12):671-680. PubMed ID: 27617757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major.
    Sievert W; Pianko S; Warner S; Bowden S; Simpson I; Bowden D; Locarnini S
    Am J Gastroenterol; 2002 Apr; 97(4):982-7. PubMed ID: 12003436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C.
    Brandhagen DJ; Gross JB; Poterucha JJ; Charlton MR; Detmer J; Kolberg J; Gossard AA; Batts KP; Kim WR; Germer JJ; Wiesner RH; Persing DH
    Am J Gastroenterol; 1999 Apr; 94(4):1000-5. PubMed ID: 10201473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caffeine clearance in patients with chronic viral hepatitis: before and after interferon therapy.
    Wittayalertpanya S; Mahachai V
    J Med Assoc Thai; 2001 Jun; 84 Suppl 1():S189-96. PubMed ID: 11529334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of the phosphorylation of signal transducers and activators of transcription in the outcome of interferon therapy for chronic hepatitis C.
    Miyaaki H; Ichikawa T; Nakao K; Takeshita S; Shibata H; Ozawa E; Akiyama M; Miuma S; Eguchi K
    Intervirology; 2008; 51(6):394-9. PubMed ID: 19258717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic metallothionein in patients with chronic hepatitis C: relationship with severity of liver disease and response to treatment.
    Carrera G; Paternain JL; Carrere N; Folch J; Courtade-Saïdi M; Orfila C; Vinel JP; Alric L; Pipy B
    Am J Gastroenterol; 2003 May; 98(5):1142-9. PubMed ID: 12809840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histological change after interferon therapy in chronic hepatitis C in view of iron deposition in the liver.
    Kakizaki S; Takagi H; Ichikawa T; Abe T; Yamada T; Suzuki K; Kojima A; Takayama H; Takezawa J; Nagamine T; Mori M
    Biol Trace Elem Res; 2000 Feb; 73(2):151-62. PubMed ID: 11049207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.